{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T05:11:56Z","timestamp":1751951516243},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,9,18]],"date-time":"2006-09-18T00:00:00Z","timestamp":1158537600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Semin Surg Oncol"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1186\/1477-7800-3-31","type":"journal-article","created":{"date-parts":[[2006,9,19]],"date-time":"2006-09-19T06:31:48Z","timestamp":1158647508000},"source":"Crossref","is-referenced-by-count":8,"title":["Adjuvant endocrine therapy for postmenopausal breast cancer in the era of aromatase inhibitors: an update"],"prefix":"10.1186","volume":"3","author":[{"given":"Ramia","family":"Mokbel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Karat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kefah","family":"Mokbel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,9,18]]},"reference":[{"issue":"5","key":"64_CR1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s101470200040","volume":"7","author":"K Mokbel","year":"2002","unstructured":"Mokbel K: The evolving role of aromatase inhibitors in breast cancer. Int J Clin Oncol. 2002, 7 (5): 279-83.","journal-title":"Int J Clin Oncol"},{"key":"64_CR2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","volume":"365","author":"ATAC Trialists' Group","year":"2005","unstructured":"ATAC Trialists' Group: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005, 365: 60-2. 10.1016\/S0140-6736(04)17666-6.","journal-title":"Lancet"},{"key":"64_CR3","doi-asserted-by":"crossref","unstructured":"Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M: Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol. 23 (30): 7512-7. 10.1200\/JCO.2005.01.4829. 2005 Oct 20","DOI":"10.1200\/JCO.2005.01.4829"},{"key":"64_CR4","doi-asserted-by":"crossref","unstructured":"Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardly A, Price KN, Goldhirsch A: Breast International Group (BIG) 1\u201398 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 353 (26): 2747-57. 2005 Dec 29","DOI":"10.1056\/NEJMoa052258"},{"key":"64_CR5","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1056\/NEJMoa040331","volume":"350","author":"RC Coombes","year":"2004","unstructured":"Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart A: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004, 350: 1081-92. 10.1056\/NEJMoa040331.","journal-title":"N Engl J Med"},{"key":"64_CR6","unstructured":"Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J: ABCSG and the GABG. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 366 (9484): 455-62. 10.1016\/S0140-6736(05)67059-6. 2005 Aug 6\u201312"},{"issue":"suppl 1","key":"64_CR7","first-page":"S11","volume":"94","author":"W Jonat","year":"2005","unstructured":"Jonat W, Gnant M, Boccardo F, Kaufmann M, Rubagotti A, Jakesz R: Switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-responsive early breast cancer: a meta-analysis of the ARNO 95 Trial, ABCSG Trial 8, and the ITA Trial. Breast Cancer Res Treat. 2005, 94 (suppl 1): S11-Abstract 18","journal-title":"Breast Cancer Res Treat"},{"key":"64_CR8","doi-asserted-by":"crossref","unstructured":"Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ: Optimizing Adjuvant Endocrine Therapy in Postmenopausal Women With Early-Stage Breast Cancer: A Decision Analysis. J Clin Oncol. 23 (22): 5178-87. 10.1200\/JCO.2005.02.964. 2005 Aug 1","DOI":"10.1200\/JCO.2005.02.964"},{"key":"64_CR9","doi-asserted-by":"crossref","unstructured":"Cuzick J, Sasieni P, Howell A: Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?. Br J Cancer. 94 (4): 460-4. 10.1038\/sj.bjc.6602964. 2006 Feb 27; Review","DOI":"10.1038\/sj.bjc.6602964"},{"issue":"3","key":"64_CR10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s10549-006-9207-y","volume":"99","author":"JN Ingle","year":"2006","unstructured":"Ingle JN, Tu D, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE: Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat. 2006, 99 (3): 295-300. 10.1007\/s10549-006-9207-y.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"64_CR11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1093\/annonc\/mdj048","volume":"17","author":"PE Lonning","year":"2006","unstructured":"Lonning PE: Comparing cost\/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2\u20133 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Ann Oncol. 2006, 17 (2): 217-25. 10.1093\/annonc\/mdj048.","journal-title":"Ann Oncol"}],"container-title":["International Seminars in Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1477-7800-3-31.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1477-7800-3-31\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1477-7800-3-31.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T07:51:47Z","timestamp":1587196307000},"score":1,"resource":{"primary":{"URL":"https:\/\/issoonline.biomedcentral.com\/articles\/10.1186\/1477-7800-3-31"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,18]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["64"],"URL":"https:\/\/doi.org\/10.1186\/1477-7800-3-31","relation":{},"ISSN":["1477-7800"],"issn-type":[{"value":"1477-7800","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9,18]]},"article-number":"31"}}